NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Conditions: Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL)
Interventions: EXS73565
Countries: Georgia, Greece, Moldova, Poland, Spain, Ukraine, United Kingdom
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Key Inclusion Criteria: * Age ≥18 years at the time of signing the informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia. * Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy Key Exclusion Criteria: * Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study. * Known central nervous system (CNS) malignancy or primary CNS lymphoma. * Concurrent active or previous malignancy (other than the primary lymphoma/CLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval. * Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.
- Tbilisi, Georgia
- Athens, Greece
- Pátrai, Greece
- Thessaloniki, Greece
- Chisinau, Moldova
- Krakow, Poland
- Lodz, Poland
- Lublin, Poland
- Skórzewo, Poland
- Madrid, Spain
- Madrid, Spain
- Madrid, Spain
- Madrid, Spain
- Pamplona, Spain
- Kyiv, Ukraine
- Leeds, United Kingdom
- Plymouth, United Kingdom